glp-1 inhibitor drugs How Receptor Agonists Evolved from Diabetes to Weight Loss Treatments Market Overview: GLP-1 Agonists and

Are people going blind from GLP-1 medications

Glucagon-like peptide-1 agonist drugs have been surging in popularity, and manufacturers are scurrying to keep up with demand

Newly released clinical trial data on the GLP-1 agonist drug Wegovy found that weight loss was sustained for up to four years after participants started taking the once-weekly injected medication

These findings support their use as a valuable adjunctive obesity management medication (OMMs) in post-bariatric care, though long-term adherence and cost-effectiveness require further investigation

Conventional wisdom says GLP-1 drugs must be taken indefinitely to maintain weight loss

Mineral and vitamin deficiencies on a GLP-1 are common in individuals with obesity and diabetes, yet theyre often overlooked